Literature DB >> 1449409

Suicide and patients with neurologic diseases. Methodologic problems.

E N Stenager1, E Stenager.   

Abstract

OBJECTIVE: The suicide risk in patients with many neurologic diseases has been reported to be greater than that in the general population. Studies on the subject are, however, often encumbered with methodologic problems. We appraised these problems and, based on an evaluation, reappraised knowledge of the suicide risk in patients with specific neurologic diseases. DATA SOURCE: Using the computerized database MEDLINE, we identified all published reports with the key words suicide, attempted suicide, and neurologic diseases. STUDY SELECTION: We assessed and reviewed studies concerning the most common neurologic diseases for methodologic problems in the study design. DATA EXTRACTION: The following methodologic problems emerged during our review: (1) choice of study type, ie, autopsy study or follow-up study; (2) choice of study population; (3) choice of control groups; (4) epidemiologic/statistical methods used; and (5) validity of statistics reported. DATA SYNTHESIS: We analyzed the methodologic problems in studies of patients with multiple sclerosis, epilepsy, Huntington's chorea, spinal cord lesions, cranial trauma, brain tumors, Parkinson's disease, vascular disorders, and migraine. In most of the studies, the methods used gave rise to uncertainty about the conclusion presented.
CONCLUSION: An increased suicide risk was found in patients suffering from multiple sclerosis and spinal cord lesions as well as in selected groups of patients with epilepsy. In other neurologic diseases, the suicide risk may be increased, but the results are uncertain due to the methodologic problems in the study design.

Entities:  

Mesh:

Year:  1992        PMID: 1449409     DOI: 10.1001/archneur.1992.00530360098025

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

Review 1.  The interpersonal theory of suicide.

Authors:  Kimberly A Van Orden; Tracy K Witte; Kelly C Cukrowicz; Scott R Braithwaite; Edward A Selby; Thomas E Joiner
Journal:  Psychol Rev       Date:  2010-04       Impact factor: 8.934

2.  Current research on chronic pain and suicide.

Authors:  D A Fishbain
Journal:  Am J Public Health       Date:  1996-09       Impact factor: 9.308

3.  Suicide in patients with stroke: epidemiological study.

Authors:  E N Stenager; C Madsen; E Stenager; J Boldsen
Journal:  BMJ       Date:  1998-04-18

Review 4.  Acute behaviour disturbances.

Authors:  G G Lloyd
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

Review 5.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 6.  The relationships between depression and brain tumors.

Authors:  N Scott Litofsky; Andrew G Resnick
Journal:  J Neurooncol       Date:  2009-03-05       Impact factor: 4.130

7.  Suicide in Neurologic Illness.

Authors:  David B. Arciniegas; C. Alan Anderson
Journal:  Curr Treat Options Neurol       Date:  2002-11       Impact factor: 3.598

Review 8.  Neuropsychiatric syndromes associated with multiple sclerosis.

Authors:  Anthony Feinstein
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

9.  Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Sarah L Minden; Anthony Feinstein; Rosalind C Kalb; Deborah Miller; David C Mohr; Scott B Patten; Christopher Bever; Randolph B Schiffer; Gary S Gronseth; Pushpa Narayanaswami
Journal:  Neurology       Date:  2013-12-27       Impact factor: 9.910

Review 10.  Depression and Suicidality in Multiple Sclerosis: Red Flags, Management Strategies, and Ethical Considerations.

Authors:  Rosalind Kalb; Anthony Feinstein; Amanda Rohrig; Lauren Sankary; Alissa Willis
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-28       Impact factor: 5.081

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.